HTA165 Unmet Medical Need in Norwegian Clinical Practice and Cost-Effectiveness Analysis of Polatuzumab in Combination With R-CHP Compared to R-CHOP in Patients With Previously Untreated DLBCL With an IPI Score of Three and Above
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1849
https://www.valueinhealthjournal.com/article/S1098-3015(23)04979-3/fulltext
Title :
HTA165 Unmet Medical Need in Norwegian Clinical Practice and Cost-Effectiveness Analysis of Polatuzumab in Combination With R-CHP Compared to R-CHOP in Patients With Previously Untreated DLBCL With an IPI Score of Three and Above
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04979-3&doi=10.1016/j.jval.2023.09.1849
First page :
Section Title :
Open access? :
No
Section Order :
11290